COMMUNIQUÉS West-GlobeNewswire

-
Entera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal Women
23/10/2025 -
SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery
23/10/2025 -
Global Drug Delivery Systems (DDS) Market Transforms Amid New Pharma Demands
23/10/2025 -
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
23/10/2025 -
Gelteq Announces Commencement of Preclinical Trial Targeting Oil Soluble Drug Market with Novel Delivery Platform
23/10/2025 -
Visory Health Partners with Albertsons Companies to Expand Access to Affordable Prescriptions Nationwide
23/10/2025 -
Synfini Selected for SLAS 2026 Innovation AveNEW Showcase
23/10/2025 -
Solana Company (NASDAQ: HSDT) Strengthens Treasury Strategy with Helius, Anchorage Digital and Twinstake Staking Services
23/10/2025 -
Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
23/10/2025 -
BeautyHealth to Report Third Quarter 2025 Financial Results on November 6, 2025
23/10/2025 -
IMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
23/10/2025 -
PCI Biotech update
23/10/2025 -
Abalos Therapeutics Doses First Patient in Phase 1 Study Evaluating ABX-001 for the Treatment of Solid Tumors
23/10/2025 -
Hydreight Reports Corporate Update and Ranks #25 on Deloitte’s 2025 Technology Fast 50™
23/10/2025 -
Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke
23/10/2025 -
'The World’s Greatest Health Van' Travels to Ottawa: 150,000 Canadians Call for The Charter of Health Freedom
23/10/2025 -
Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
23/10/2025 -
TLX250-CDx (Zircaix) Included in Leading International Guidelines for Renal Imaging
23/10/2025 -
Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers
23/10/2025
Pages